Mirati therapeutics, inc. (MRTX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue
Total revenue

3,335

12,926

0

0

-

-

-

-

Operating expenses
Research and Development Expense

182,866

93,872

58,085

68,487

48,959

26,071

19,797

15,081

General and administrative

42,573

21,681

13,450

15,292

15,755

12,699

11,177

5,417

Restructuring costs

-

-

-

-

-

334

1,025

0

Total operating expenses

225,439

115,553

71,535

83,779

64,714

39,104

31,999

20,498

Loss from operations

-222,104

-102,627

-71,535

-83,779

-64,714

-39,104

-31,999

-20,498

Other income, net

8,848

4,209

1,105

661

170

-77

-1,084

251

Change in fair value of warrant liability

-

-

-

-

-

4,517

19,799

0

Loss before income taxes

-

-

-

-

-

-43,698

-52,882

-20,247

Income tax benefit

-

-

-

-

-

0

-23

39

Net Income (Loss) Attributable to Parent

-213,256

-98,418

-70,430

-83,118

-64,544

-43,698

-52,859

-20,286

Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

410

0

-54

-25

37

14

-13

0

Comprehensive loss

-212,846

-98,418

-70,484

-83,143

-64,507

-43,684

-52,872

-20,286

Basic and diluted net loss per share (USD per share)

-5.69

-3.19

-2.78

-4.20

-

-3.24

-4.78

-3.00

Loss per share, basic (in US$ per share)

-

-

-

-

-3.82

-

-

-

Weighted average number of shares used in computing net loss per share, basic and diluted (shares)

37,467

30,897

25,290

19,787

16,901

13,483

11,057

6,762